What Кларитромицин treats: Main Uses and Benefits

Clarithromycin is used in clinical settings that involve acute or unstable symptom patterns in situations involving certain distressing symptoms. It is applied across domains where additional symptomatic support is needed, primarily focusing on respiratory, dermal, and specialized gastrointestinal conditions.

The medicine is commonly used to help manage symptoms associated with conditions like community-acquired pneumonia, acute bronchitis episodes, pharyngitis, tonsillitis, uncomplicated skin infections, and as part of a regimen to eradicate Helicobacter pylori. It is also considered relevant in the supportive management of disseminated Mycobacterium avium complex (MAC) in vulnerable patients.

It provides support that helps ease the overall symptom burden, including persistent cough, fever, localized pain, and inflammation.

“The medication assists with maintaining functional stability by contributing to easing the overall symptom load during episodes of heightened discomfort.”

---

Quick Fact: Support for Inflammation and Pain Clarithromycin is applied in scenarios where additional management of discomfort is required to address the noticeable physiological strain associated with redness, swelling, and localized pain in susceptible skin and respiratory infections.

Regulatory References

1. DailyMed official drug label

The eligibility for using Clarithromycin (Кларитромицин) is determined by strict rules outlined in official regulatory documents concerning pre-existing conditions and patient age.

Contraindications (Must Not Use)

Clarithromycin is contraindicated and must not be used by patients with:

• Known hypersensitivity to clarithromycin, erythromycin, or any macrolide antibiotic.
• A history of cholestatic jaundice or hepatic dysfunction previously associated with clarithromycin use.
• Severe hepatic failure in combination with renal impairment (kidney function compromise).
• Congenital or documented acquired QT prolongation, ventricular arrhythmias (including Torsades de Pointes), or uncorrected hypokalaemia (low potassium) [Source 2.3, 2.4].

Conditional Use and Age Restrictions

Use requires caution in patients with impaired hepatic function or moderate to severe renal impairment alone, and in those with coronary artery disease or severe cardiac insufficiency [Source 2.4]. Patients with myasthenia gravis also require caution [Source 1.2].

Population Group	Eligibility Status (Regulatory Label)
Infants under 6 months	Safety and efficacy not established [Source 1.2].
Children under 12 years	Oral suspension is the recommended formulation; tablets are not recommended [Source 2.4].
Pregnant Women	Use is not advised unless the benefit clearly outweighs the potential risk [Source 1.1].
Breastfeeding Women	Use requires caution as the medicine is excreted into breast milk [Source 3.4].

Clarithromycin Interactions with other medicines and products

Clarithromycin is a potent inhibitor of the Cytochrome P450 3A4 (CYP3A4) enzyme and the P-glycoprotein transporter. This inhibitory action can significantly increase the plasma concentration of many co-administered medicines that are substrates for these pathways, leading to a risk of serious or life-threatening adverse reactions.

---

Contraindicated Combinations

Co-administration of clarithromycin with the following medicines is strictly contraindicated due to the potential for severe toxicity or cardiac events:

Medicine Category	Examples of Medicines
HMG-CoA Reductase Inhibitors	Lovastatin, Simvastatin
Ergot Alkaloids	Ergotamine, Dihydroergotamine
Specific Psychotropics	Pimozide, Lurasidone
Antiarrhythmics / Antihistamines	Cisapride, Terfenadine, Astemizole
Other	Colchicine (in patients with renal or hepatic impairment)

---

Other Significant Interactions

Careful monitoring and often dose adjustment are required when clarithromycin is used with other medicines, including those metabolized by CYP3A4 but not contraindicated, such as oral anticoagulants (e.g., Warfarin), Digoxin, and Theophylline. Concurrent use with other medicines that prolong the QT interval requires caution due to additive cardiac risk. Furthermore, an altered administration schedule, such as spacing by at least 2 hours, may be required for certain combinations like Zidovudine.

The Primary Mechanism: Targeting Bacterial Protein Synthesis

Clarithromycin performs its principal biological activity by engaging the bacterial ribosome. It achieves this by binding specifically and reversibly to the 23S ribosomal RNA of the 50S subunit, which physically blocks the crucial process of peptide chain elongation. This precise inhibition halts the production of proteins essential for bacterial growth and replication, leading to the suppression of the pathogen population and thereby facilitates the process of host immune clearance.

---

Secondary Action: Modulating Host Inflammation

Beyond direct antimicrobial action, the molecule exhibits a secondary immunomodulatory mechanism by influencing the host's immune cells. This involves the dampening of key inflammatory pathways and reducing the release of pro-inflammatory signaling molecules (cytokines). This effect is intrinsic to the molecule's complete biological activity, which results in a reduction of inflammatory mediator effects on host tissue and modifies the concentration of pro-inflammatory signals in host tissues.

---

Mechanistic Constraints and Bacterial Evasion

The biological activity of Clarithromycin is constrained by bacterial mechanisms of evasion. This most notably includes point mutations in the ribosomal binding site (23S rRNA) that reduce the drug's affinity, and the activity of efflux pumps that actively expel the drug from the bacterial cell. These resistance mechanisms directly counteract the drug's action by preventing adequate concentration at its molecular target.

Clarithromycin is administered primarily via the oral route, available as immediate-release (IR) tablets, extended-release (XL) tablets, and a paediatric suspension. Intravenous (IV) infusion is an approved route for adults requiring parenteral therapy, administered as a 500 mg dose infused slowly over 60 minutes.

The standard adult dosing for IR forms is typically 250 mg twice daily (every 12 hours), which may be increased to 500 mg twice daily for severe infections. XL tablets follow a once-daily schedule of 1000 mg. The general duration of a course is 6 to 14 days.

Administration timing is strictly form-dependent: IR tablets and suspension can be taken without regard to food, whereas XL tablets must be taken with food to ensure the controlled release of the active substance. A key procedural constraint is that XL tablets must be swallowed whole and must not be crushed, chewed, or broken.

Specific adjustments are mandatory for certain populations: Children under 12 years are restricted to the oral suspension. Patients with severe renal impairment (creatinine clearance <30 mL/ min) require the dosage to be reduced by one-half, and the treatment duration must not exceed 14 days. If a dose is missed, patients are instructed to resume the schedule at the next designated time.

Research Evidence / Overview of Studies for Clarithromycin

Evidence for use in Respiratory and Skin Infections

Research exploring Clarithromycin in managing acute infections like Community-Acquired Pneumonia (CAP) relies on Randomized Controlled Trials (RCTs) and systematic reviews. These studies primarily monitored short-term outcomes related to symptom resolution and microbiological markers in hospitalized and non-hospitalized adults and children. The research describes patterns of change in measured clinical and microbiological markers observed during the study periods. Comparative studies explored the effect of using Clarithromycin alongside other antibiotics; however, data on long-term outcomes, such as mortality, varied across different observational cohorts.

Evidence for use in Helicobacter pylori (H. pylori) Regimens

Clarithromycin was studied for regimens designed to measure patterns of H. pylori clearance in multi-drug therapies. Studies monitored these regimens and reported patterns of measured eradication in populations with susceptible bacteria. A key limitation is that rising global resistance to Clarithromycin means the results apply only to specific populations studied, and the certainty of successful clearance remains low where macrolide resistance is common.

Long-Term Studies and Uncertainty

Beyond acute treatment, Clarithromycin was studied for its potential long-term outcomes through follow-up periods extending up to 10 years, primarily in patients with existing stable heart disease. Findings highlight patterns where a short course of treatment was observed alongside long-term mortality measurements compared to placebo. However, the biological mechanism for these observed long-term outcomes is not fully established, and subsequent observational studies have reported mixed findings. Research is also insufficient for certain special populations, such as pregnant or breastfeeding populations, and limited data exists on long-term effects in the pediatric group.

Key Studies & References

1. DailyMed: Clarithromycin tablet, film coated, extended release

Common questions about Кларитромицин (FAQ)

Q: What kind of infections is Кларитромицин designed to treat?

A: Official regulatory documents state that this medicine is used to treat bacterial infections caused by organisms susceptible to its action. These indications include lower respiratory tract infections, such as pneumonia, certain skin infections, and some mycobacterial infections. The specific conditions treated are outlined in the official product information.

Q: Do you need a special diet when taking Кларитромицин?

A: According to official product information, there is generally no requirement for a special restrictive diet. However, if you are taking the extended-release (XL) tablets, it is specified that they should be taken with food to ensure the medicine works as intended. Immediate-release (IR) tablets and the oral suspension may be taken independently of food.

Q: Is Кларитромицин used to treat respiratory infections like bronchitis?

A: Yes, regulatory documents indicate that this medicine is used to treat respiratory tract infections, including acute exacerbations of chronic bronchitis, when these conditions are caused by susceptible bacteria. It is generally used against a range of infections that affect the airways.

Q: Why do official documents mention the risk of QT prolongation with Кларитромицин?

A: Official warnings mention this risk because the medicine has been observed to prolong the QT interval, which is a measure of electrical activity in the heart. This change carries a risk of developing serious, abnormal heart rhythms, such as Torsades de pointes.

Q: What should I do if I develop diarrhea while taking Кларитромицин?

A: Diarrhea is a common side effect, but severe forms, including those associated with Clostridium difficile bacteria, are noted as serious risks in official warnings. Official warnings advise seeking medical attention for evaluation if diarrhea develops that is persistent or severe during or after treatment.

Q: How does Кларитромицин compare to other macrolide antibiotics?

A: Clarithromycin is classified as a macrolide antibiotic, meaning it shares structural similarities with other drugs in this group. Regulatory documents describe it as a semisynthetic derivative of erythromycin, a chemical modification designed to improve its performance within the body compared to its precursor.

Q: What does 'resistance' mean in the context of Кларитромицин?

A: In the context of this medicine, bacterial resistance refers to the bacteria's ability to withstand its effects. The official mechanism involves bacteria changing the drug's target or creating efflux pumps to actively expel the medicine from the bacterial cell, thereby preventing the drug from working.

Q: Why does Кларитромицин sometimes require adjustment for people with liver issues?

A: The medicine is processed by the liver, and regulatory documents require caution in patients with impaired liver function. Use is contraindicated (not recommended in that scenario) in patients experiencing severe liver failure, particularly when combined with kidney problems, due to the risk of hepatotoxicity (liver damage).

Q: Can common cold or flu be treated with Кларитромицин?

A: No. Official regulatory documents clarify that this medicine is an antibiotic specifically indicated for treating bacterial infections. It is officially stated to be not effective against infections caused by viruses, which include the common cold and influenza (flu).

Q: Why is it important to complete the full course of Кларитромицин even if I feel better?

A: Official regulatory bodies state that completing the full course supports maximum clearance of the infection and helps prevent recurrence. Stopping early increases the risk that some bacteria will survive, potentially leading to the development of drug resistance.

Q: What are the signs of a serious, but rare, skin reaction from Кларитромицин?

A: Official warnings list rare, but potentially life-threatening, skin reactions such as Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN). Patients are advised that signs to watch for include a spreading, painful rash, or blistering of the skin and mucous membranes. Regulatory documents advise consulting a healthcare professional immediately if these signs appear.

Q: Is there any research on the use of Кларитромицин for non-bacterial conditions?

A: The official description of the drug's action includes a secondary mechanism beyond its primary bacterial effects. This secondary action involves immunomodulatory properties where the drug influences the host's immune cells and dampens inflammatory pathways.

Q: What are the ingredients in Кларитромицин besides the active drug?

A: The active ingredient is solely Clarithromycin. However, regulatory documents list various excipients (inactive ingredients) in the formulation, which are substances added for stability, structure, or flavor. These can include coloring agents, binding agents, and preservatives.

Q: What type of headaches are associated with taking Кларитромицин?

A: Regulatory safety information lists headache as a common adverse reaction (meaning it is expected in 1% to 10% of patients). While the occurrence is noted, the official patient information generally does not provide specific details on the type or severity of headache associated with the medicine.

Q: Can teenagers use the same dose of Кларитромицин as adults?

A: Regulatory dosage guidelines often address the use in different populations. Regulatory guidance notes that adolescents (over 12 years) are often addressed using the same dosage considerations as adults. Specific administration instructions depend on the form of the medicine prescribed.

Q: Is Кларитромицин the same type of antibiotic as penicillin?

A: No. According to regulatory descriptions, this medicine is classified as a macrolide antibiotic. This means it works differently from Penicillins, which belong to an entirely separate drug class known as beta-lactams.

Q: How quickly does Кларитромицин start working after you take it?

A: Official pharmacokinetic studies indicate that the medicine is generally rapidly absorbed into the body. For immediate-release tablets, the absorption is rapid, with concentrations typically reaching their maximum level a few hours after administration.

Q: Can Кларитромицин affect birth control pills?

A: Official drug interaction sections include information regarding the potential for clarithromycin to affect the body's processing of certain hormones used in oral contraceptives. While the effect may be minimal for some, regulatory caution is usually advised regarding the risk of increased hormone concentration.

Q: Is it true that Кларитромицин can cause dizziness or confusion?

A: Yes. Official safety documentation lists both dizziness and confusion as documented side effects of the medicine. These effects are generally classified as uncommon or rare adverse reactions, meaning they are not expected to occur in most patients.

Q: Can older adults safely use Кларитромицин?

A: Regulatory documents advise that caution is required when this medicine is prescribed to the elderly population. This is primarily due to the potential for drug interactions with other commonly used medications and the presence of underlying conditions affecting the heart or kidney function.

Q: Do food products like grapefruit interact with Кларитромицин?

A: Yes. Official regulatory documents indicate that the consumption of grapefruit or grapefruit juice may interact with this medicine. This interaction can affect how the body processes the drug, which may increase the risk of experiencing certain side effects.

Q: Is the tiredness or fatigue experienced with Кларитромицин a common side effect?

A: Official adverse reaction lists include terms such as fatigue or asthenia (a lack of physical strength or energy) as documented side effects. These effects are typically categorized as uncommon, meaning they are expected to occur in less than 1% of patients in clinical trials.

Q: Are there generic versions of Кларитромицин available?

A: Yes. Clarithromycin is an established medicine, and regulatory bodies confirm its availability under multiple generic names. The availability of generic versions generally occurs after the expiration of the original patent protection for the medicine.

Q: How long does Кларитромицин stay in the body after the last dose?

A: The medicine's half-life (how long it takes for half of the drug to be eliminated from the body) is described in the regulatory texts as being several hours, depending on the dosage and form. This metric gives an indication of how long the medicine remains active in the system.

Q: What are the official guidelines regarding the use of Кларитромицин in diabetic patients?

A: Official drug interaction sections specifically warn about the co-administration of this medicine with certain oral hypoglycemic agents (medications for diabetes). The combination can potentiate the effects of these agents, which may lead to episodes of clinically significant low blood sugar (hypoglycemia).

Q: Are there any official restrictions on driving while taking Кларитромицин?

A: Official patient information advises awareness regarding the risk of side effects such as dizziness or confusion while taking this medicine. Regulatory documents recommend caution, as these effects may affect the ability to drive or operate complex machinery.

Q: Can you take antacids at the same time as Кларитромицин?

A: Official documents frequently advise against taking certain antacids at the exact same time as this medicine. Regulatory documents advise administering the antacids separately from this medicine, typically requiring a time spacing to prevent interference with absorption.

Q: Does Кларитромицин affect blood sugar levels?

A: Yes, official documents confirm a relationship via drug interactions. Regulatory sections warn that when clarithromycin is taken with certain medications prescribed for diabetes, it can potentially lead to clinically significant changes in blood sugar levels.

Q: Is Кларитромицин primarily used for Gram-positive or Gram-negative bacteria?

A: The regulatory texts describe the medicine's activity against a broad range of clinically significant bacteria. This includes many Gram-positive pathogens and certain Gram-negative pathogens, as well as atypical organisms.

Q: How is Кларитромицин usually prescribed for sinusitis?

A: The drug is officially indicated for the treatment of acute maxillary sinusitis when the infection is confirmed to be caused by bacteria susceptible to its action. The prescribing information confirms this as one of its approved uses.

Q: Is it common for people to experience changes in appetite while on Кларитромицин?

A: Official lists of adverse reactions include anorexia (loss of appetite) as a documented side effect. This is typically categorized as uncommon, meaning it is reported in less than 1% of patients in clinical trials.

Storage and Disposal of Clarithromycin

The storage and disposal of Clarithromycin must strictly follow official regulatory guidelines to maintain potency and ensure safety.

Required Storage Conditions

Formulation	Temperature Range	Specific Constraints
Tablets / Dry Granules	20 to 25 C (68 to 77 F)	Protect from light and moisture; store in a tightly closed container.
Constituted Suspension	15 to 30 C (59 to 86 F)	Do not refrigerate or freeze.

Stability and Safety Requirements

• Stability Limit: The liquid oral suspension, once mixed, must be discarded after 14 days.
• Child Safety: All forms of the medication must be kept out of the sight and reach of children.
• Disposal: Expired or unused Clarithromycin must be thrown away according to local regulatory disposal requirements and established guidelines for unused medicines, typically avoiding flushing down the toilet or placing in household waste.